Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.

Summary

Eli Lilly announced the acquisition of AtaiBeckley for $2.8 billion, signaling major pharmaceutical industry interest in psychedelic-based therapeutics. Cathie Wood has identified another psychedelic drug stock as a potentially superior investment opportunity.